In this week’s episode, we will learn more about T-cells from SARS-CoV-2-infected individuals, review a study that describes the rapid clinical and histologic response to anti-PD1 first-line therapy in early-stage, unfavorable Hodgkin lymphoma, and discuss a meta-analysis and systematic review of outcomes of patients with hematologic malignancies and Covid-19.
